尤瑞克林联合降纤酶对急性脑梗塞患者的神经功能缺损及血浆纤维蛋白原的影响  

Effect of the urinary kallidinogenase combined with defibrase on the nerve function defect and plasma fibrinogen in patients with acute cerebral infarction

作　　者：李丽媛[1] 王建平[1] 

机构地区：[1]郑州大学第五附属医院神经内科,河南郑州450000

出　　处：《中国地方病防治》2017年第1期20-21,共2页Chinese Journal of Control of Endemic Diseases

基　　金：国家自然科学基金资助项目(面上项目)(编号:81571137)

摘　　要：目的探讨尤瑞克林联合降纤酶对急性脑梗塞患者神经功能缺损及血浆纤维蛋白原的影响。方法 67例急性脑梗塞患者随机分为对照组33例,观察组34例,对照组予尤瑞克林治疗,观察组予尤瑞克林联合降纤酶治疗,比较两组治疗前后神经功能缺损(NIHSS)评分、血浆纤维蛋白原水平,统计临床疗效及不良反应发生率。结果观察组总有效率94.12%高于对照组72.73%(P<0.05);治疗后1、2周、1个月观察组NIHSS评分及血浆纤维蛋白原水平均低于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论尤瑞克林联合降纤酶治疗急性脑梗塞患者疗效显著,可有效改善患者血浆纤维蛋白原水平及神经功能缺损程度,安全性高。Objective To investigate the effect of the urinary kallidinogenase combined with defibrase on the nerve function defect and plasma fibrinogen in patients with acute cerebral infarction. Methods Sixty-seven patients with acute cerebral infarction were randomly divided into control group（ 33 cases） and observation group（ 34 cases）,the control group was treated with the urinary kallidinogenase,the observation group was treated with urinary kallidinogenase combined with defibrase. The nerve function defect（ NIHSS） score,plasma fibrinogen level were observed and compared before and after treatment,and the clinical efficacy and adverse reaction rate of two groups were observed and compared.Results The total effective rate of the observation group（ 94.12%） was higher than that of the control group（ 72.73%）（ P〈0.05）; 1 weeks,2 weeks and 1 months after treatment,the NIHSS score and plasma fibrinogen level in the observation group were lower than those in control group（ P〈0.05）;There was no significant difference in the incidence of adverse reactions between the two groups（ P〈0.05）. Conclusion The curative effect of urinary kallidinogenase combined with defibrase in treating acute cerebral infarction is significant,which can effectively improve the plasma fibrinogen level and neural function defect degree,high safety.

关 键 词：尤瑞克林 降纤酶 急性脑梗塞 神经功能 血浆纤维蛋白原 

分 类 号：R743.33[医药卫生—神经病学与精神病学]